0
0
Eli Lilly announced on September 17, 2025, that its new oral medication orforglipron surpassed Novo Nordisk’s oral semaglutide in lowering blood sugar and achieving weight loss among 1,698 adults with type 2 diabetes in a 52-week head-to-head Phase 3 ACHIEVE-3 trial. The study, conducted at multiple sites internationally, provides fresh hope for patients seeking effective, easy-to-use alternatives to injected therapies.
Key Findings and Developments
-
Orforglipron (36 mg daily) produced an average reduction in HbA1c (a measure of long-term blood sugar control) of 2.2% versus 1.4% with oral semaglutide’s highest approved dose (14 mg).
-
Patients on orforglipron lost an average of 19.7 lbs (9.2% body weight), compared to 11 lbs (5.3%) with oral semaglutide—a 73.6% greater relative reduction.
-
37.1% of participants taking orforglipron achieved near-normal blood sugar (HbA1c <5.7%), compared to just 12.5% for oral semaglutide.
-
Results were consistent across ages, with both drugs added to standard metformin therapy.
-
Safety and tolerability profiles for orforglipron matched those of injectable GLP-1 drugs, with no major new risks reported.
Expert Commentary
Prof Naveed Sattar, Professor of Cardiometabolic Medicine at the University of Glasgow, praised the results, calling the weight loss “well beyond levels seen with most existing diabetes therapies” and crucial to future care. “Having new oral agents that lower glucose but also meaningfully lower weight is critical to future type 2 diabetes care,” said Sattar, adding that stronger cardiovascular safety data is needed and is anticipated from future trials.
Other independent experts have noted the importance of ease of use: “Many people prefer oral medications over injections,” explained Dr. Irena Maragkou, Senior Healthcare Researcher, GlobalData, highlighting how the pill format could improve global access to diabetes and obesity treatments.
Statistical Context and Study Size
-
ACHIEVE-3 enrolled 1,698 adults with type 2 diabetes; sub-studies like ATTAIN-1 involved over 3,000 adults with obesity or overweight without diabetes.
-
Weight loss in ATTAIN-1 averaged 27.3 lbs (12.4%) over 72 weeks, showing consistent benefit across doses.
-
In ATTAIN-2, patients with diabetes and obesity lost up to 22.9 lbs (10.5%) and improved cardiometabolic health markers.
Context and Background
GLP-1 receptor agonists are a class of drugs that mimic the hormone GLP-1 to suppress appetite, slow stomach emptying, and enhance insulin production. Until recently, the most effective versions required injections. Oral semaglutide (Rybelsus) brought the first pill format but had limitations in efficacy and strict administration instructions.
Orforglipron’s small-molecule, non-peptide design allows for once-daily dosing without food or water restrictions, potentially lowering barriers to adherence and global distribution.
Implications for Public Health
If approved, orforglipron could become the first oral GLP-1 therapy to rival or exceed the effectiveness of injectable drugs, expanding access for people hesitant or unable to use needles. Given the rise in obesity and diabetes worldwide, improved accessibility may translate to better health outcomes, especially in underserved areas.
Experts caution that longer-term cardiovascular outcomes, affordability, and real-world tolerability will need careful surveillance after regulatory approval. Lilly aims to submit for global regulatory review in late 2025.
Potential Limitations and Counterarguments
-
Full data on cardiovascular outcomes and rare side effects are not yet available.
-
Most trials compare therapies as adjuncts to metformin; real-world results may vary.
-
While oral GLP-1 drugs improve convenience, injectable versions remain slightly more potent in certain studies.
-
Expert opinions suggest rigorous long-term monitoring is essential for wide adoption.
Practical Implications for Readers
For people with type 2 diabetes or obesity, orforglipron’s convenience and robust clinical outcomes may offer an attractive alternative, pending availability and insurance coverage. As with all medications, individuals should discuss options with their healthcare providers, considering personal medical history and treatment goals.
Medical Disclaimer
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
-
Lilly press release: “Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant superiority to oral semaglutide in Phase 3 ACHIEVE-3 trial,” Eli Lilly and Company, September 17, 2025.https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-superior-oral-semaglutide-head
